Carvedilol therapy in pediatric patients with dilated cardiomyopathy

Area of Science:

• Pediatric Cardiology
• Pharmacology
• Cardiovascular Medicine

Background:

• Congestive heart failure (CHF) management in adults often includes carvedilol.
• Limited data exists on carvedilol's use in pediatric populations.
• Idiopathic dilated cardiomyopathy (DCM) is a significant cause of heart failure in children.

Purpose of the Study:

• To evaluate the dosing, efficacy, and safety of carvedilol for pediatric DCM.
• To assess changes in cardiac function and clinical status in children treated with carvedilol.
• To identify any adverse effects associated with carvedilol use in this age group.

Main Methods:

• A cohort of 16 children (7-138 months) with DCM and ejection fraction <40% received carvedilol.
• Dosing started at 0.1 mg/kg/day and was titrated up to 0.4 mg/kg/day.
• Cardiac function (ejection fraction, fractional shortening) and clinical scores were assessed over six months.

Main Results:

• Significant improvements were observed in clinical scoring (2.94 to 2.50, p<0.05).
• Mean fractional shortening increased from 17.2% to 22.7% (p<0.05).
• Ejection fraction improved from 35.2% to 43.1% (p<0.05), with no reported side effects.

Conclusions:

• Carvedilol, as an adjunct to standard therapy, enhances cardiac function and alleviates symptoms in pediatric DCM.
• The medication demonstrates good tolerability with minimal adverse events in children.
• Close patient monitoring is recommended during carvedilol treatment for pediatric heart failure.